Introduction
============

Epstein--Barr virus is a gamma-herpes family virus that infects over 95% of humans globally and is the etiological agent of many acute and chronic infections as well as human malignancies ([@B17]). While EBV infection is widespread, the outcome of infection can depend upon the age of the host. Pediatric cases are mainly asymptomatic and the infection subsides due to a vigorous host T cell response with the virus subsequently transitioning to latency in a subset of memory B cells ([@B15]; [@B9]). However, in adolescents, primary infection can manifest as glandular fever, lymphadenopathy, and a sore throat, termed infectious mononucleosis (IM) ([@B3]). IM is associated with a transient proliferation of EBV-infected B cells followed by a considerable expansion of EBV-specific T cells ([@B25]; [@B19]; [@B4]; [@B11]; [@B3]). IM is typically self-limiting and resolves over a period of weeks to months with the virus persisting into a latent phase in infected B cells ([@B13]).

MicroRNAs are small 18--25 nt long single-stranded RNA molecules which regulate gene expression at the post-transcriptional level. miRNA target specific mRNAs by complementary base-pairing, leading to cleavage or repression of translation, and can act as major regulators of key cellular processes. We ([@B12]) and others ([@B8]; [@B21]) have shown that EBV infection can alter the expression of host miRNAs and thus modulate various arms of the cellular machinery including cell differentiation and death, proliferation, and the immune response. Along these lines, miR-194 is suppressed by EBV and participates in regulation of IL-10 expression in EBV lymphomas ([@B12]) while two miRNA families, the let-7 family and the miR-200 family, as well as miR-143-3p, act as tumor-suppressor miRNAs and are significantly downregulated in EBV-infected gastric carcinoma cells ([@B22]). Other studies have found that miR-155 and miR-21 were induced in B cells by EBV infection and potentially play a role in viral tumorigenesis ([@B20]; [@B24]; [@B2]). Furthermore, p53-targeted tumor suppressor, miR-34a, is strongly induced by EBV infection in many EBV and Kaposi's sarcoma-associated herpesvirus-infected lymphoma cell lines and plays a role in B cell transformation ([@B8]). In addition, miRNAs have been identified that play a critical role in the T cell response to pathogens. For example, miR-155 is essential for the CD8^+^ effector T cell response to mCMV ([@B6]).

In addition to host miRNAs, EBV-expressed miRNAs have also been shown to modulate the function of T and B cells during an immune response. In a study by [@B1], EBV-encoded miRNAs were found to inhibit CD8^+^ T cell-mediated viral surveillance at multiple levels. The viral miRNAs downregulate TAP-complex and HLA allotype that present TAP-dependent epitopes, reduce IL-12 secretion by infected B cells to diminish EBV-specific CD8 T cells and repress EBNA1, a viral protein responsible for latency ([@B1]). EBV encoded miRNAs miR-BART1, miR-BART2, and miR-BHRF1-2 have also been shown to target the host adaptive immune response by repressing IL-12 secretion resulting in reduced differentiation of CD4^+^ T cells into the Th1 subset and inhibiting lysosomal enzymes involved in MHC class-II peptide processing ([@B27]), while miR-BART16 suppresses Type I IFN signaling ([@B14]). In the current study, we report the differential expression of host and viral miRNAs in acute IM caused by primary EBV infection. Our findings elucidate the miRNA signature associated with acute IM and demonstrate the dynamic features of this response with the miRNA expression profile reverting to that of healthy individuals within a few months of IM diagnosis in subjects without complications.

Materials and Methods {#s1}
=====================

Patient Samples
---------------

Peripheral blood samples were obtained from symptomatic patients (aged 18--24 years) who visited Vaden Student Health Center at Stanford University and were diagnosed with clinical IM. Samples were obtained upon diagnosis (time point 0) and then at, 1, 2, and 7 months. Blood samples were processed using Ficoll-Paque PLUS (Amersham Pharmacia Biotech, Piscataway, NJ, United States) then PBMC frozen and maintained in liquid nitrogen until use. PBMCs were isolated from blood derived from healthy age-matched individuals. This study was carried out in accordance with the recommendations of Institutional Review Board at Stanford University with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki.

RNA Isolation and miRNA Microarray
----------------------------------

Patient (*n* = 16) and healthy control (*n* = 3) PBMCs were suspended and lysed in TRIzol Reagent (Life Technologies, Foster City, CA, United States) for isolation of total RNA. Glycogen (20 μg) was used for RNA precipitation. Isolated RNA was DNase treated (Qiagen) and clean-up was done on RNeasy spin columns (Qiagen) using a modified protocol which replaced RW1 buffer with RWT buffer for washing. RNA was suspended in RNase free water and stored at -80°C. RNA quantification was done using Nanodrop 2000 Spectrophotometer (Thermo Fisher scientific, Wilmington, DE, United States). Approximately 200 ng RNA was used for microarray analysis using Affymetrix GeneChip miRNA 4.0 arrays (Affymetrix, Santa Clara, CA, United States) through the PAN (Protein and Nucleic acid) facility at Stanford University. Briefly, 130 ng total RNA was assessed for quality using Bioanalyzer 2100 (Agilent), followed by Poly-A tailing and labeling with biotin using a Affymetrix FlashTag Biotin HSR RNA Labeling kit (Affymetrix, Santa Clara, CA, United States) according to the manufacturer's protocol. The labeled targets are hybridized to the GeneChip^®^ miRNA 4.0 arrays per standard miRNA protocol, which includes 16 h (overnight) hybridization at 48°C at 60 RPM in the Affymetrix GeneChip Hybridization oven 645. The arrays were then washed and stained in the Affymetrix GeneChip Fluidics Station 450. The arrays were scanned using the Affymetrix GeneChip Scanner 3000 7G. The GeneChip^®^ miRNA 4.0 arrays contain 30,424 total mature miRNA probe sets including 2578 mature human miRNAs, 2025 pre-miRNA human probes, 1996 Human snoRNA and scaRNA probe sets and miRNAs of 202 other organisms.

Data Analysis
-------------

Raw microarray data were statistically analyzed using Partek Genomics Suite software (Partek Inc.). Normalization was done suing Robust Multi-array Average (RMA) and log2 transformation of data was performed, followed by one-way ANOVA statistical testing to identify significantly differentially expressed miRNA between different groups (*P* ≤ 0.05). After running ANOVA, the software performs multi-testing correction using Benjamini--Hochberg Step-Up FDR-controlling procedure for all the expressed miRNAs (default FDR Alpha level 0.05). Venn diagram depicting intersection of differentially expressed miRNAs and Unsupervised Hierarchical Clustering analysis was also performed. Raw Fold change and adjusted *p*-value data was exported to dot excel file and data selection and graphic visualization was done using Power BI software (Microsoft Inc.). Differentially expressed EBV miRNAs were also identified using the same miRNA microarray dataset using the miRNA filter as "EBV," mRNA expression data from a publicly available GEO dataset (GSE45924) was used to perform miRNA--mRNA integrated analysis. Briefly, SOFT formatted family file (GSE45924-GPL6883_series_matrix.piv.txt.fmt) were downloaded from the GEO Database and imported into Partek Genomics Suite for mRNA "Gene Expression" workflow. Illumina HumanRef-8 v3.0 expression beadchip annotation files were uploaded to the Partek Software to obtain Fold Change Values for mRNA differential expression between comparison groups of Acute IM subjects (PBMC) and control subjects (PBMC). Pre-normalized data was log2 transformed, followed by one-way ANOVA statistical testing to identify significantly differentially expressed mRNAs and multiple-testing correction using Benjamini--Hochberg Step-Up FDR-controlling procedure (default FDR Alpha level 0.05). Fold increases of \>2, and fold decreases of \>2 were considered significant. The differentially expressed mRNA data was exported into a text file and converted into a suitable format for upload to IPA for further analysis.

Functional and Pathway Enrichment Analysis of Target Genes Controlled by Differentially Expressed miRNAs
--------------------------------------------------------------------------------------------------------

Pathway and molecular function enrichment analysis was performed using IPA software (Qiagen, Redwood city, CA, United States). A list of all twofold differentially expressed miRNAs obtained from Partek Genomics Suite software analysis was uploaded into IPA for analysis. miRNA target enrichment was performed using the "miRNA Target Filter" function, generating a list of 181 miRNAs with available targeting information. An mRNA gene expression dataset (GSE45924) obtained from GEO database was added to the "miRNA Target Filter" setting in IPA and "Expression pairing" was performed. An additional filter applied to this list was "Applied filters: confidence = Experimentally Observed OR High (predicted)." Further "Core Analysis" was performed on the target mRNAs based on different experimental time points to determine the affected networks and canonical pathways. Throughout the analysis, a *p*-value cutoff of 0.05 was applied. The HumanRef-8 v3.0 reference gene list was used to set the population of genes to consider for *p*-value calculations while performing Core Analysis.

Results
=======

Sample QC and Principal Component Analysis
------------------------------------------

As a means of quality control to determine the biological separation of the groups based on probe intensities, principal component analysis (PCA) was performed using Partek Genomics software. Two separate groups of samples from IM patients at 0 month (at the time of diagnosis) and healthy controls are clearly observed (**Figure [1](#F1){ref-type="fig"}**). The remaining samples from 1, 2, and 7 months are loosely segregated into groups and fall between these two groups on PC1 with the samples obtained at 7 months grouping closely with those from healthy controls. These findings indicate that the differentially expressed miRNAs are maximal at the time of IM diagnosis and return to the healthy control pattern in subsequent months.

![Principal component analysis (PCA) on miRNA expression data from human peripheral blood mononuclear cells (PBMCs) from acute infectious mononucleosis (IM) patients and healthy controls using the first three components. Red, at diagnosis; Blue, 1 month; Green, 2 months; Purple, 7 months; Orange, Healthy control.](fmicb-08-02666-g001){#F1}

Differentially Expressed miRNAs
-------------------------------

The differential expression of miRNAs were compared between patients at the time of IM diagnosis (0 month), and at 1 and 2 months after diagnosis, compared to age-matched healthy controls (**Figure [2A](#F2){ref-type="fig"}**). We identified 215 differentially regulated miRNAs at the most acute stage of infection (diagnosis, 0 month). The number of differentially expressed miRNAs decreased to 148 and 68 during the course of 1 and 2 months post-primary infection, with no significantly changed miRNAs identified at 7 months post-infection (data not shown). The 27 top differentially expressed miRNAs at diagnosis, and 1 and 2 months after diagnosis, show that most of the differentially expressed miRNAs are increased (25 increased, 2 decreased) (**Figure [2B](#F2){ref-type="fig"}**).

![Top differentially expressed microRNAs (miRNAs). **(A)** Differentially expressed miRNAs in IM Patients at Time 0, 1, and 2 months compared to healthy controls, **(B)** Top differentially expressed miRNAs observed at all three time points, at diagnosis, 1, and 2 months vs. healthy controls \[false discovery rate (FDR) 0.05, Absolute Fold change \>10\].](fmicb-08-02666-g002){#F2}

Unsupervised hierarchical clustering depicted as a heatmap shows the relative intensity for the 215, 148, and 68 differentially expressed miRNAs at diagnosis (**Figure [3](#F3){ref-type="fig"}**), 1 month (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}) and 2 months (Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}) as compared to healthy controls, respectively. A fold change of two and FDR adjusted *p*-value (Benjamini--Hochberg method for multiple corrections) of 0.05 was considered significant in Partek Genomics Suite Software, with black depicting decreased expression levels and blue depicting upregulation. Furthermore, the differentially expressed miRNAs demonstrate a decreasing absolute fold change over time, with the highest fold change generally observed at the time of diagnosis (**Figure [4](#F4){ref-type="fig"}**). These 41 miRNAs exhibit a dynamic differential expression pattern that trends toward healthy control levels at 2 months post IM diagnosis. Two miRNAs that are highly upregulated, miR-4417 and miR-4485 (data not shown), exhibit a similar trend of decreasing differential expression from diagnosis to 2 months. A compilation of all statistically significant differentially expressed miRNAs at diagnosis and one, and 2 months versus healthy controls is included in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}. Supplementary Table [S2](#SM1){ref-type="supplementary-material"} provides a list of all differentially expressed miRNAs. A Venn diagram depicts the number of miRNAs in common at IM diagnosis and at 1 and 2 months (**Figure [5](#F5){ref-type="fig"}**). The intersection shows that 56 miRNAs are differentially expressed at the three time points, thus providing important information regarding possible disease specific signatures. Interestingly, miRNAs uniquely expressed at diagnosis, 1 and 2 months after diagnosis also decrease in number during the course of the infection toward recovery (79 at diagnosis, 15 at 1 month and 9 at 2 months).

![Unsupervised Hierarchical Clustering Heatmap showing relative intensity for 215 miRNAs in Patients at diagnosis versus healthy controls. Analysis using Partek Genomics suite, step up FDR 0.05. Black shows downregulation and blue shows upregulation. Healthy controls (green), IM at diagnosis (red).](fmicb-08-02666-g003){#F3}

![Differentially expressed miRNAs at three time points, at Diagnosis, 1 and 2 months showing a trend toward decreasing absolute fold change (FDR 0.05).](fmicb-08-02666-g004){#F4}

![Venn diagram depicting number of miRNAs common between point of diagnosis, 1 and 2 months versus healthy control. Number in brackets () is the total number of differentially expressed miRNAs at that time point vs. control.](fmicb-08-02666-g005){#F5}

Pathways Altered by IM
----------------------

Expression pairing of miRNA data, from our study and gene expression data from GEO set GSE45924 returned 46 miRNAs targeting 17 mRNAs (**Figure [6A](#F6){ref-type="fig"}**). Comparative analysis of mRNA targets highlighted the most canonical pathways as well as disease and biological functions (**Figures [6B,C](#F6){ref-type="fig"}**). Furthermore, functional pathway analysis in IPA using the list of differentially expressed miRNAs at 0 month suggests the most impacted networks include antigen presentation, infectious disease, humoral immune response, protein synthesis, cell cycle, and cell death mechanisms. Networks have been shown in addition to their scores and number of mRNA targets (including particular molecules that pass our set filter criterion) (**Table [1](#T1){ref-type="table"}**). Further analysis in IPA for top canonical pathways targeted by our list of differentially expressed miRNAs at IM diagnosis and based on the Illumina HumanRef-8 v3.0 gene superset shows candidates including interferon signaling, altered T and B cell signaling, primary immunodeficiency signaling, antigen presentation and communication between innate and adaptive immune cells as the major affected canonical pathways (Supplementary Figure [S3](#SM1){ref-type="supplementary-material"}).

![mRNA targets and associated pathways of the differentially expressed miRNAs. **(A)** Venn diagram and table comparison of mRNA targets of differentially expressed miRNAs at Diagnosis, 1 and 2 months. **(B)** Comparison of canonical pathways, **(C)** Comparison of Diseases and Bio Functions; mRNA targets were obtained from miRNA--mRNA expression pairing of differentially expressed miRNAs and GEO dataset GSM1119621--GSM1119636 in ingenuity pathway analysis (IPA).](fmicb-08-02666-g006){#F6}

###### 

List of top five networks with their respective scores obtained from ingenuity pathway analysis (IPA): Data are indicative of networks regulated by mRNA targets of microRNAs (miRNAs) differentially expressed at the time of infectious mononucleosis (IM) diagnosis.

  Top diseases and functions                                                                                          Score   Focus molecules^∗^   Molecules in network
  ------------------------------------------------------------------------------------------------------------------- ------- -------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antigen presentation, protein synthesis, infectious disease                                                         36      13                   BCR (complex), **↓CD79A**, ERK1/2, **↑FBX06**, **↓FCRLA**, **↑GBP2**, **↑GBP4**, **↑GBP5,** IFNα, β, IFN type1, Ifnar, Ifnz, IgG, IgM, IL12 (family), **↑LMNB1**, **↓LTB**, MHC Class I (complex), NF-κB (complex) Nr1hPirb, **↑PSMB8**, **↑RARRES3,** RNA polymerase II, SLFN13, **↑STAT1**, **↑TAP1**, TBCB, TCR, **↓TLR10**, Trbv1
  Hematological system development and function, humoral immune response, lymphoid tissue structure and development   3       1                    FOXO1, IGHM, KLF3, SOX11, **↓VPREB3**
  Cell morphology, cellular function and maintenance, connective tissue disorders                                     2       1                    APP, HNF4A, HOXD4, LIG4, SAFB2, ZNF24, ZNF396, ZSCAN1, ZSCAN18, ZSCAN20, **↓ZSCAN32**
  Cell cycle cellular assembly and organization, DNA replication, recombination and repair                            2       1                    BLM, CCND1, CENPS/CENPS-CORT, dihydrotestosterone, ERCC6L, FAAP100, FANCA, FANCM, NOTCH3, RIF3, RMI1, **↑RMI2**, RPA1, RPA2, RPA3, SPIDR, TOP3A, TOPBP1, TTK
  Cell cycle, gene expression, cell death and survival                                                                2       1                    All *trans*-retinyl esters, CREBBP, **↓DHRS3**, ELAVLi, EP300, FSH, GPS2, Lh, N-cor, NADP-retinol dehydrogenase, OSM, PLA2G10, PPARG, RAF1, RDH, RDH10, retinyl ester, SNCA, TNF, TP73, tretinoin
                                                                                                                                                   

∗

Focus Molecules (in bold)- molecules that passed the filters and cut-offs that are members of this network.

Differentially Expressed EBV miRNAs
-----------------------------------

Interestingly, when the EBV miRNAs are analyzed using specific filtering criteria in Partek, only ebv-miR-BART-16 and ebv-miR-BART5-3p are uniquely upregulated at IM diagnosis and at 1 and 2 months as compared to healthy controls (ANOVA 0.05, unadjusted *p*-value) (**Table [2](#T2){ref-type="table"}**). It is notable that no differential expression of any EBV miRNAs is observed at 7 months post-infection, which is expected due to resolution of the symptoms in the acute phase and establishment of EBV latency. Thus, of the more than 40 known EBV miRNAs only two, miR-BART5-3p and miR-BART-16 are expressed during acute IM ([@B26]).

###### 

Differentially expressed EBV miRNAs in patients at diagnosis, 1 and 2 months versus healthy controls, ANOVA 0.05, unadjusted *p*-value.

                     0 Month (diagnosis)   1 Month   2 Months                                   
  ------------------ --------------------- --------- ---------- ------ ------ --- ------ ------ ---
  ebv-miR-BART16     2.93                  0.00      ↑          2.75   0.01   ↑   2.11   0.04   ↑
  ebv-miR-BART5-3p   2.44                  0.02      ↑          2.57   0.01   ↑   2.85   0.01   ↑
                                                                                                

Discussion
==========

This study provides the first miRNA expression profile of sequential, peripheral blood samples from college-age patients with acute IM. Our results clearly indicate that primary EBV disease is accompanied by marked expression changes of multiple host and viral miRNA, and that the number of differentially expressed miRNAs decreases substantially after the initial diagnosis. It is noteworthy that there were no differentially expressed miRNAs observed at 7 months as compared to healthy controls, indicating that there is no identifiable miRNA signature that can distinguish between normal college students and those that have resolved IM. Since none of the patients studied had any complications after IM, it remains possible that expression of the differentially expressed host miRNAs would remain dysregulated if IM were not completely resolved.

We determined that 43 of the host miRNAs, including miR-197-3p, miR-491-5p, miR-151a-5p, miR-652-3p, and miR-744-5p, decreased from the levels found at diagnosis over the subsequent 2 months. While the specific function of these miRNA in IM is unknown, other reports have linked these miRNA to disease processes. Recently, miR-197 was found to act synergistically with EBV-BART6-3p to reduce the expression of IL-6R, thereby compromising host immune defense in EBV-positive Burkitt Lymphoma ([@B29]). miR-625-3p has been shown to be a potential biomarker for a number of cancerous conditions including malignant pleural mesothelioma ([@B18]). miR-625-3p targets p38 MAPK activator MAP2K6 and induces oxaliplatin resistance by abrogating MAP2K6-p38-regulated apoptosis and cell cycle control networks ([@B23]). A recent study also shows that miR-625-3p is upregulated in CD8^+^ T cells during early immune reconstitution following allogeneic stem cell transplantation ([@B28]). An interesting study with highly virulent H5N2 strain of mouse-adapted avian influenza virus found miR-151a-p as one of the significantly upregulated miRNAs, whose inhibition resulted in a 70% reduction in mortality of inoculated mice ([@B5]).

The majority of studies to date examining the impact of EBV infection or pathogenesis on miRNA expression have focused on the miRNA profile within the virally infected cell and the implications for tumorigenesis. In contrast, we analyzed the impact of EBV infection on peripheral lymphoid cells that typically participate in the immune response to EBV. A single previous study did examine the cellular miRNAs from pre-adolescent children with IM in China over the first 14 days after primary infection ([@B10]). They determined the host miRNA expression in B cells and CD8^+^ T cells and EBV miRNAs in plasma and B cells. Interestingly, some miRNAs such as miR-155 and miR-142 were increased in B cells and decreased in CD8^+^ T cells, thus, changes would not be reflected in unfractionated PBMC. Our analysis of miRNAs in PBMC demonstrated a different set of host miRNAs as differentially expressed. These distinct patterns are most likely attributed to different methodologies, since our study took an unbiased approach and performed microarray analysis using Affymetrix GeneChip miRNA 4.0 arrays (over 30,000 mature miRNAs) on unfractionated PBMC, whereas the Gao group specifically examined a small subset of 84 miRNAs in sorted B and T cells via PCR. Further, the ages of the subjects were different and there could be other differences including environmental factors and variant strains of EBV. EBV expresses more miRNAs than other characterized human viruses, with at least 44 EBV miRNAs identified to date ([@B26]). We determined that ebv-miR-BART16 and ebv-miR-BART5-3p were increased in PBMC as compared to healthy controls. The specific function of these viral miRNA in IM is unknown, but it is interesting that a recent report indicates that BART16 suppresses IFN signaling ([@B14]). Notably, the EBV miRNA profile we identified in acute IM is distinct from the EBV miRNA profile identified in plasma samples of patients with chronic active EBV infection ([@B16]).

In addition to EBV-induced miRNA regulation in infected B cells, others have focused on understanding the EBV pathogenesis and host responses by transcriptomic (mRNA microarray, Illumina) analysis on PBMCs of human subjects in a prospective study of naturally acquired primary EBV infection ([@B7]). The authors found a distinct gene expression profile in acute but not latent EBV infection. Moreover, upon gene expression profiling in sorted CD8^+^ T cells, NK cells, monocytes, and B cells, it was found that CD8^+^ T cells and monocytes showed upregulation of key gene groups (Type I interferon regulated genes (IRGs), type II IRGs, and cell cycle/metabolism genes.) during acute infection. This pathway analysis agrees with the pathways predicted to be altered by our miRNA profile during acute IM.

Conclusion
==========

We have defined the host immune cell and EBV miRNA profile elicited by primary EBV infection during acute IM. This profile is indicative of a response that is accompanied by complete resolution of disease. Thus, it may be useful in predicting which individuals that present with IM will have an uncomplicated course and ultimately may shed insight into the host immune response to acute EBV infection.
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